Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | C. Cannon | E. Ohman | A. Kirtane | S. Murphy | M. Roe | C. Gibson | D. Karmpaliotis | Aaron Weisbord | C. Gibson
[1] R. Califf,et al. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. , 2005, American Heart Journal.
[2] G. Heusch. Coronary microembolization*1 , 2004 .
[3] R. Gibbons,et al. 829-5 Primary angioplasty in acute myocardial infarction with distal protection of the microcirculation: Principal results from the prospective, randomized EMERALD trial , 2004 .
[4] M. Takano,et al. Elevated Troponin T Levels and Lesion Characteristics in Non–ST-Elevation Acute Coronary Syndromes , 2004, Circulation.
[5] E. Topol,et al. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. , 2003, Journal of the American College of Cardiology.
[6] R. Califf,et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. , 2003, Journal of the American College of Cardiology.
[7] K. Shimada,et al. Predicting angiographic distal embolization following percutaneous coronary intervention in patients with acute myocardial infarction. , 2003, The American journal of cardiology.
[8] C. Cannon,et al. Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion: A TACTICS-TIMI 18 Substudy , 2002, Circulation.
[9] H. Heidbuchel,et al. Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial , 2002, Circulation.
[10] E. Braunwald,et al. Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction: A Thrombolysis In Myocardial Infarction 10 Substudy , 2000, Circulation.
[11] T. Reil,et al. The effects of thrombus, thrombectomy and thrombolysis on endothelial function. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[12] C M Gibson,et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.
[13] E. Antman,et al. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. , 1999, Journal of the American College of Cardiology.
[14] E. Antman,et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.
[15] E. Topol,et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.
[16] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.
[17] D. Ardissino,et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. , 1995, Journal of the American College of Cardiology.
[18] K. Bailey,et al. Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 32 cases. , 1993, Journal of the American College of Cardiology.
[19] J. Eidt,et al. Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications , 1989, Circulation.